Latest Insider Transactions at Igm Biosciences, Inc. (IGMS)
This section provides a real-time view of insider transactions for Igm Biosciences, Inc. (IGMS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of IGM Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of IGM Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 11
2021
|
Michael D Loberg Director |
BUY
Bona fide gift
|
Indirect |
535
+20.0%
|
-
|
|
Jan 11
2021
|
Michael D Loberg Director |
SELL
Bona fide gift
|
Direct |
535
-100.0%
|
-
|
|
Jan 05
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,102
-0.94%
|
$87,058
$79.25 P/Share
|
|
Jan 05
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,503
-35.18%
|
$118,737
$79.33 P/Share
|
|
Jan 04
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
798
-0.67%
|
$61,446
$77.27 P/Share
|
|
Jan 04
2021
|
Daniel Shin Yu Chen Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,900
+1.58%
|
$1,900
$1.39 P/Share
|
|
Jan 04
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
997
-18.92%
|
$76,769
$77.27 P/Share
|
|
Jan 04
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+32.18%
|
$0
$0.93 P/Share
|
|
Jan 04
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Indirect |
883
-46.57%
|
$77,704
$88.07 P/Share
|
|
Dec 31
2020
|
Michael Stewart Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
178
+20.0%
|
-
|
|
Dec 31
2020
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
357
+0.38%
|
-
|
|
Dec 31
2020
|
Michael D Loberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
535
+50.0%
|
-
|
|
Dec 31
2020
|
Christina Teng Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
357
+0.99%
|
-
|
|
Dec 31
2020
|
Jakob Haldor Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
178
+0.32%
|
-
|
|
Dec 31
2020
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
446
+0.05%
|
-
|
|
Dec 31
2020
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
178
+0.01%
|
-
|
|
Dec 21
2020
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,750
+49.62%
|
$2,750
$1.39 P/Share
|
|
Dec 17
2020
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,618
-36.88%
|
$139,148
$86.1 P/Share
|
|
Dec 16
2020
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
882
-16.74%
|
$78,498
$89.38 P/Share
|
|
Dec 16
2020
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+32.18%
|
$0
$0.93 P/Share
|
|
Dec 11
2020
|
M Kathleen Behrens |
BUY
Open market or private purchase
|
Indirect |
44,444
+39.66%
|
$3,999,960
$90.0 P/Share
|
|
Dec 11
2020
|
Topsoe Holding A/S > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
111,111
+1.06%
|
$9,999,990
$90.0 P/Share
|
|
Dec 11
2020
|
Christina Teng Topsoe |
BUY
Open market or private purchase
|
Indirect |
111,111
+1.06%
|
$9,999,990
$90.0 P/Share
|
|
Dec 11
2020
|
Jakob Haldor Topsoe |
BUY
Open market or private purchase
|
Indirect |
111,111
+1.06%
|
$9,999,990
$90.0 P/Share
|
|
Dec 08
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,219
-1.04%
|
$110,929
$91.0 P/Share
|
|
Dec 07
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
681
-0.58%
|
$49,032
$72.92 P/Share
|
|
Dec 07
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,900
+1.58%
|
$1,900
$1.39 P/Share
|
|
Dec 02
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
608
-0.52%
|
$38,304
$63.15 P/Share
|
|
Dec 01
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
342
-0.29%
|
$21,888
$64.22 P/Share
|
|
Dec 01
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
950
+0.8%
|
$950
$1.39 P/Share
|
|
Nov 13
2020
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
132
+4.55%
|
$5,940
$45.45 P/Share
|
|
Nov 13
2020
|
Fred Schwarzer CEO AND PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
291
+0.15%
|
$13,095
$45.45 P/Share
|
|
Nov 13
2020
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
42
+50.0%
|
$1,890
$45.45 P/Share
|
|
Nov 04
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
605
-0.52%
|
$30,250
$50.0 P/Share
|
|
Nov 02
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
345
-0.29%
|
$17,940
$52.39 P/Share
|
|
Nov 02
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
950
+0.8%
|
$950
$1.39 P/Share
|
|
Oct 09
2020
|
Michael D Loberg Director |
BUY
Bona fide gift
|
Indirect |
535
+25.0%
|
-
|
|
Oct 09
2020
|
Michael D Loberg Director |
SELL
Bona fide gift
|
Direct |
535
-100.0%
|
-
|
|
Oct 02
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,830
-1.55%
|
$133,590
$73.5 P/Share
|
|
Oct 01
2020
|
Michael Stewart Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
178
+25.0%
|
-
|
|
Oct 01
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,020
-0.85%
|
$77,520
$76.13 P/Share
|
|
Oct 01
2020
|
Daniel Shin Yu Chen Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,850
+2.33%
|
$2,850
$1.39 P/Share
|
|
Oct 01
2020
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Indirect |
1,000
-34.53%
|
$73,000
$73.59 P/Share
|
|
Oct 01
2020
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
357
+0.38%
|
-
|
|
Oct 01
2020
|
Michael D Loberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
535
+50.0%
|
-
|
|
Oct 01
2020
|
Christina Teng Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
357
+1.0%
|
-
|
|
Oct 01
2020
|
Jakob Haldor Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
178
+0.32%
|
-
|
|
Oct 01
2020
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
446
+0.05%
|
-
|
|
Oct 01
2020
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
178
+0.01%
|
-
|
|
Sep 09
2020
|
Redmile Group, LLC Director |
BUY
Open market or private purchase
|
Indirect |
23,260
+0.34%
|
$1,209,520
$52.4 P/Share
|